Calmark: The distributor agreement for Sweden with Triolab is not extended

Press release from Companies

Publicerat: 2022-09-26 12:51:05

Calmark Sweden AB: The distributor agreement for Sweden with Triolab is not extended

Calmark Sweden AB (publ) announced today that the exclusive distributor agreement for the Swedish market with the company Triolab AB will not be extended.

The agreement was valid until September 23, 2022, and the search for a new distributor for Sweden is ongoing.

Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.

For more information about Calmark Sweden AB, please contact:

Anna Söderlund, CEO
Telefon: [phone]
E-post: [e-mail]
www.calmark.se

Calmark Sweden AB is a medical technology company that develops and markets a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, was launched to the market in 2020. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. In addition to products for newborns, Calmark sells a POC test for assessment of COVID-19 disease severity. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker.Read more at www.calmark.se/eng/home.

Read as PDF

Release